The FDA has issued a draft guidance to simplify the procedure of developing drugs for rare pediatric disorders.
Reports indicate that the Senate Finance Committee has settled on a deal to fund the Children’s Health Insurance Program, which is on track to exhaust funds by the end of September.
The FDA has approved the first treatment option for patients age 3 years or older with congenital or idiopathic pulmonary arterial hypertension.
The FDA has approved a drug for the treatment of Chagas disease.
An intravenous injection for the treatment of hypoglycemia is being recalled.